Jim Simons
NXTC icon

Jim Simons’s NextCure NXTC Stock Holding History

Jim Simons’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Buy
171,202
+110,668
+183% +$818K ﹤0.01% 2804
2026
Q1 		$647K Buy
60,534
+26,900
+80% +$329K ﹤0.01% 2491
2025
Q4 		$477K Buy
33,634
+5,300
+19% +$54.9K ﹤0.01% 2591
2025
Q3 		$166K Sell
28,334
-13,411
-32% -$70.2K ﹤0.01% 3169
2025
Q2 		$230K Buy
41,745
+1,748
+4% +$9.38K ﹤0.01% 3131
2025
Q1 		$231K Sell
39,997
-3,278
-8% -$28.9K ﹤0.01% 3037
2024
Q4 		$400K Buy
43,275
+9,442
+28% +$139K ﹤0.01% 2950
2024
Q3 		$556K Sell
33,833
-4,679
-12% -$86.1K ﹤0.01% 2740
2024
Q2 		$735K Buy
38,512
+5,145
+15% +$100K ﹤0.01% 2491
2024
Q1 		$893K Buy
33,367
+8,924
+37% +$154K ﹤0.01% 2553
2023
Q4 		$334K Buy
24,443
+3,593
+17% +$52.1K ﹤0.01% 2943
2023
Q3 		$323K Buy
20,850
+250
+1% +$4.77K ﹤0.01% 2899
2023
Q2 		$445K Buy
20,600
+225
+1% +$4.43K ﹤0.01% 2938
2023
Q1 		$362K Sell
20,375
-13,507
-40% -$260K ﹤0.01% 3037
2022
Q4 		$573K Buy
33,882
+14,715
+77% +$339K ﹤0.01% 2876
2022
Q3 		$633K Sell
19,167
-5,145
-21% -$262K ﹤0.01% 2779
2022
Q2 		$1.37M Buy
24,312
+11,912
+96% +$622K ﹤0.01% 2487
2022
Q1 		$723K Buy
12,400
+3,267
+36% +$204K ﹤0.01% 2945
2021
Q4 		$658K Sell
9,133
-22,042
-71% -$1.84M ﹤0.01% 2942
2021
Q3 		$2.52M Buy
31,175
+14,483
+87% +$1.27M ﹤0.01% 1914
2021
Q2 		$1.61M Buy
+16,692
New +$1.71M ﹤0.01% 2403
2020
Q3 		– Sell
-5,342
Closed -$1.37M – 3586
2020
Q2 		$1.37M Buy
+5,342
New +$2.03M ﹤0.01% 2389

Other funds holding NXTC

Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Sofinnova Investments
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Squadron Capital Management
Squadron Capital Management Westmont, Illinois $322M AUM
Verdad Advisers
Verdad Advisers Boston, Massachusetts $104M AUM
Pfizer
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Jim Simons's NXTC Position: Q2 2026 in Review

Jim Simons increased its NextCure (NXTC) stake by 183% in Q2 2026, buying an estimated $818K and bringing the position to 171,202 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

Jim Simons first reported a position in NXTC in Q2 2020 and has held it in 22 quarters since. The position peaked at $2.52M in Q3 2021. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Jim Simons held 171,202 shares of NextCure worth $274K as of Q2 2026.
  • Jim Simons bought 110,668 NextCure shares in Q2 2026, an estimated $818K.
  • NextCure made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2804 holding.
  • Jim Simons first reported a position in NextCure in Q2 2020 and has held it in 22 quarters since.
  • Jim Simons's NextCure position peaked at $2.52M in Q3 2021.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.